-
-
-
-
-
-
-
Fate Therapeutics (FATE) Tops Q2 EPS by 5c
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Tops Q3 EPS by 2c
-
-
-
-
-
-
-
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Tops Q2 EPS by 5c, misses on revenue
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IBM, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
-
1,198,695 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

